Annual Cash & Cash Equivalents
$32.79 M
+$8.33 M+34.04%
31 December 2023
Summary:
Rigel Pharmaceuticals annual cash & cash equivalents is currently $32.79 million, with the most recent change of +$8.33 million (+34.04%) on 31 December 2023. During the last 3 years, it has risen by +$2.41 million (+7.94%). RIGL annual cash & cash equivalents is now -57.30% below its all-time high of $76.78 million, reached on 31 December 2005.RIGL Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$51.69 M
+$15.64 M+43.38%
30 September 2024
Summary:
Rigel Pharmaceuticals quarterly cash and cash equivalents is currently $51.69 million, with the most recent change of +$15.64 million (+43.38%) on 30 September 2024. Over the past year, it has increased by +$6.28 million (+13.82%). RIGL quarterly cash and cash equivalents is now -49.62% below its all-time high of $102.60 million, reached on 31 March 2008.RIGL Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RIGL Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +34.0% | +13.8% |
| 3 y3 years | +7.9% | +70.0% |
| 5 y5 years | -57.0% | +32.2% |
RIGL Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +73.6% | at high | +173.7% |
| 5 y | 5 years | -57.0% | +73.6% | -39.1% | +173.7% |
| alltime | all time | -57.3% | +461.8% | -49.6% | +820.6% |
Rigel Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $51.69 M(+43.4%) |
| June 2024 | - | $36.05 M(+41.0%) |
| Mar 2024 | - | $25.57 M(-22.0%) |
| Dec 2023 | $32.79 M(+34.0%) | $32.79 M(-27.8%) |
| Sept 2023 | - | $45.41 M(-7.0%) |
| June 2023 | - | $48.81 M(+21.2%) |
| Mar 2023 | - | $40.28 M(+64.7%) |
| Dec 2022 | $24.46 M(+29.5%) | $24.46 M(-18.1%) |
| Sept 2022 | - | $29.87 M(+9.8%) |
| June 2022 | - | $27.20 M(+10.2%) |
| Mar 2022 | - | $24.68 M(+30.6%) |
| Dec 2021 | $18.89 M(-37.8%) | $18.89 M(-37.9%) |
| Sept 2021 | - | $30.40 M(-64.2%) |
| June 2021 | - | $84.82 M(+323.1%) |
| Mar 2021 | - | $20.05 M(-34.0%) |
| Dec 2020 | $30.37 M(+34.9%) | $30.37 M(-16.9%) |
| Sept 2020 | - | $36.57 M(+0.3%) |
| June 2020 | - | $36.47 M(-19.4%) |
| Mar 2020 | - | $45.23 M(+100.8%) |
| Dec 2019 | $22.52 M(-70.5%) | $22.52 M(-42.4%) |
| Sept 2019 | - | $39.09 M(-11.6%) |
| June 2019 | - | $44.23 M(-40.8%) |
| Mar 2019 | - | $74.70 M(-2.1%) |
| Dec 2018 | $76.32 M(+99.3%) | $76.32 M(+24.1%) |
| Sept 2018 | - | $61.49 M(-5.5%) |
| June 2018 | - | $65.08 M(+62.2%) |
| Mar 2018 | - | $40.13 M(+4.8%) |
| Dec 2017 | $38.29 M(+117.2%) | $38.29 M(+48.0%) |
| Sept 2017 | - | $25.88 M(-20.6%) |
| June 2017 | - | $32.59 M(-18.8%) |
| Mar 2017 | - | $40.14 M(+127.7%) |
| Dec 2016 | $17.63 M(-59.4%) | $17.63 M(-32.1%) |
| Sept 2016 | - | $25.95 M(+4.0%) |
| June 2016 | - | $24.95 M(+74.8%) |
| Mar 2016 | - | $14.27 M(-67.2%) |
| Dec 2015 | $43.46 M(+185.8%) | $43.46 M(+12.6%) |
| Sept 2015 | - | $38.58 M(+123.1%) |
| June 2015 | - | $17.29 M(-59.5%) |
| Mar 2015 | - | $42.72 M(+181.0%) |
| Dec 2014 | $15.20 M(-27.1%) | $15.20 M(+18.6%) |
| Sept 2014 | - | $12.81 M(-46.3%) |
| June 2014 | - | $23.88 M(+60.2%) |
| Mar 2014 | - | $14.91 M(-28.5%) |
| Dec 2013 | $20.85 M(-37.7%) | $20.85 M(+30.1%) |
| Sept 2013 | - | $16.03 M(-26.7%) |
| June 2013 | - | $21.87 M(-36.0%) |
| Mar 2013 | - | $34.16 M(+2.0%) |
| Dec 2012 | $33.48 M | $33.48 M(+24.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $26.80 M(+2.5%) |
| June 2012 | - | $26.15 M(+18.7%) |
| Mar 2012 | - | $22.03 M(+18.2%) |
| Dec 2011 | $18.63 M(+109.9%) | $18.63 M(-0.3%) |
| Sept 2011 | - | $18.68 M(-56.5%) |
| June 2011 | - | $42.95 M(+67.1%) |
| Mar 2011 | - | $25.71 M(+189.6%) |
| Dec 2010 | $8.88 M(-39.7%) | $8.88 M(-72.5%) |
| June 2010 | - | $32.23 M(+109.4%) |
| Mar 2010 | - | $15.39 M(+4.6%) |
| Dec 2009 | $14.72 M(-68.0%) | $14.72 M(-84.5%) |
| Sept 2009 | - | $94.75 M(+301.8%) |
| June 2009 | - | $23.58 M(-35.8%) |
| Mar 2009 | - | $36.73 M(-20.2%) |
| Dec 2008 | $46.01 M(+3.4%) | $46.01 M(-20.3%) |
| Sept 2008 | - | $57.72 M(+17.7%) |
| June 2008 | - | $49.06 M(-52.2%) |
| Mar 2008 | - | $102.60 M(+130.5%) |
| Dec 2007 | $44.50 M(-6.8%) | $44.50 M(+14.8%) |
| Sept 2007 | - | $38.77 M(-41.6%) |
| June 2007 | - | $66.42 M(+53.9%) |
| Mar 2007 | - | $43.17 M(-9.6%) |
| Dec 2006 | $47.73 M(-37.8%) | $47.73 M(-13.9%) |
| Sept 2006 | - | $55.42 M(-10.9%) |
| June 2006 | - | $62.23 M(-4.7%) |
| Mar 2006 | - | $65.29 M(-15.0%) |
| Dec 2005 | $76.78 M(+631.6%) | $76.78 M(-16.3%) |
| Sept 2005 | - | $91.76 M(+788.8%) |
| June 2005 | - | $10.32 M(-20.0%) |
| Mar 2005 | - | $12.91 M(+23.0%) |
| Dec 2004 | $10.49 M(+9.1%) | $10.49 M(+86.9%) |
| Sept 2004 | - | $5.62 M(-28.1%) |
| June 2004 | - | $7.81 M(-81.5%) |
| Mar 2004 | - | $42.18 M(+338.4%) |
| Dec 2003 | $9.62 M(-63.7%) | $9.62 M(-60.0%) |
| Sept 2003 | - | $24.07 M(-58.6%) |
| June 2003 | - | $58.09 M(+171.0%) |
| Mar 2003 | - | $21.43 M(-19.2%) |
| Dec 2002 | $26.54 M(+131.0%) | $26.54 M(-26.8%) |
| Sept 2002 | - | $36.27 M(+80.6%) |
| June 2002 | - | $20.08 M(-31.9%) |
| Mar 2002 | - | $29.47 M(+156.6%) |
| Dec 2001 | $11.49 M(-76.6%) | $11.49 M(+3.4%) |
| Sept 2001 | - | $11.11 M(+70.5%) |
| June 2001 | - | $6.51 M(-69.2%) |
| Mar 2001 | - | $21.14 M(-56.9%) |
| Dec 2000 | $49.03 M(+740.1%) | $49.03 M |
| Dec 1999 | $5.84 M | - |
FAQ
- What is Rigel Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Rigel Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Rigel Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of RIGL is $32.79 M
What is the all time high annual cash & cash equivalents for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high annual cash & cash equivalents is $76.78 M
What is Rigel Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, RIGL annual cash & cash equivalents has changed by +$8.33 M (+34.04%)
What is Rigel Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RIGL is $51.69 M
What is the all time high quarterly cash and cash equivalents for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high quarterly cash and cash equivalents is $102.60 M
What is Rigel Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, RIGL quarterly cash and cash equivalents has changed by +$6.28 M (+13.82%)